NCT05892614 - Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Interstitial Lung Disease

Interventions

DRUG

efzofitimod 450 mg

IV infusion over approximately 60 minutes every 4 weeks

DRUG

efzofitimod 270 mg

IV infusion over approximately 60 minutes every 4 weeks

DRUG

Placebo

IV infusion over approximately 60 minutes every 4 weeks

Trial Locations (15)

10027

RECRUITING

aTyr Investigative Site, New York

23284

RECRUITING

aTyr Investigative Site, Richmond

29425

RECRUITING

aTyr Investigative Site, Charleston

33146

RECRUITING

aTyr Investigative Site, Miami

44195

RECRUITING

aTyr Investigative Site, Cleveland

60153

RECRUITING

aTyr Investigative Site, Chicago

60611

RECRUITING

aTyr Investigative Site, Chicago

60612

RECRUITING

aTyr Investigative Site, Chicago

70115

RECRUITING

aTyr Investigative Site, New Orleans

73104

RECRUITING

aTyr Investigative Site, Oklahoma City

75204

RECRUITING

aTyr Investigative Site, Dallas

77204

RECRUITING

aTyr Investigative Site, Houston

84112

RECRUITING

aTyr Investigative Site, Salt Lake City

90024

RECRUITING

aTyr Investigative Site, Los Angeles

92093

RECRUITING

aTyr Investigative Site, San Diego

All Listed Sponsors

lead

aTyr Pharma, Inc.

INDUSTRY